IP Library Granted Patent US 8,288,343
Granted Patent B2
US 8,288,343 · App. 12/593,277 · Granted Oct 16, 2012

Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation

Assignee: National University Corporation Nagoya University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,343
App. No.
12/593,277
Granted
Oct 16, 2012
Kind
B2
Abstract

The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient.

Claims (7)

1. A method to activate nitric oxide synthase (eNOS) which method comprises contacting a vascular endothelial cell expressing said eNOS with a composition comprising a human midkine protein as an active ingredient.

2. The method of claim 1 wherein said eNOS is contained in a subject in need of activation of said eNOS and said contacting comprises administering said composition to the subject.

3. A method to stimulate vasodilation in a subject in need of said stimulation of vasodilation which method comprises administering to the coronary artery of a subject in need of such stimulated vasodilation a composition comprising a human midkine protein as an active ingredient.

4. The method of claim 3 wherein said subject has an ischemia disorder or muscle cell dysfunction after ischemia perfusion.

5. The method of claim 3 wherein said administering is to the coronary artery of the subject comprises delivery of the human midkine protein via the lumen of a percutaneous transluminal coronary angioplasty (PTCA) device into a coronary artery of the subject.

6. The method of claim 2 wherein said composition is administered in an amount of 50 ng/kg to 100 μg/kg.

7. The method of claim 3 wherein said composition is administered in an amount of 50 ng/kg to 100 μg/kg.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2012
From: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
To: CELLMID LIMITED
Reel/Frame 029092/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2010
From: HORIBA, MITSURU; KADOMATSU, KENJI; KODAMA, ITSUO; MURAMATSU, TAKASHI; ISHIGURO, HISAAKI; TAKENAKA, HIROHARU; SUMIDA, ARIHIRO
To: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
Reel/Frame 024104/0769 →
Priority Claims (1)
JP 2007-093798 · Mar 30, 2007 · national
Continuity (1)
Related Publication 20100197577A1 · Aug 5, 2010